Epigenetic Reader Domain

Epigenetic regulators of gene expression and chromatin state include so-called writers, erasers, and readers of chromatin modifications.Well-characterized examples of reader domains include bromodomains typically binding acetyllysine and chromatin organization modifier (chromo), malignant brain tumor (MBT), plant homeodomain (PHD), and Tudor domains generally associating with methyllysine. Research on epigenetic readers has been tremendously influenced by the discovery of selective inhibitors targeting the bromodomain and extraterminal motif (BET) family of acetyl-lysine readers. The human genome encodes 46 proteins containing 61 bromodomains clustered into eight families. Distinct experimental approaches are used to identify the first BET inhibitors, GSK 525762A and (+)-JQ-1.

The Polycomb group (PcG) protein, enhancer of zeste homologue 2 (EZH2), has an essential role in promoting histone H3 lysine 27 trimethylation (H3K27me3) and epigenetic gene silencing. This function of EZH2 is important for cell proliferation and inhibition of cell differentiation, and is implicated in cancer progression. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. In many types of cancers including lymphomas and leukemia, EZH2 is postulated to exert its oncogenic effects via aberrant histone and DNA methylation, causing silencing of tumor suppressor genes.

p300/CBP is not only a transcriptional adaptor but also a histone acetyltransferase.

Epigenetic Reader Domain Inhibitors & Modulators

(+)-JQ-1
(JQ1)

Cat. No.: HY-13030

(+)-JQ-1 (JQ1) is a potent, specific, and reversible **BET bromodomain** inhibitor, with IC_{50}s of 77 and 33 nM for the first and second bromodomain (**BRD4(1/2)**). (+)-JQ-1 also activates **autophagy**.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

(+)-JQ-1-aldehyde

Cat. No.: HY-131633A

(+)-JQ-1-aldehyde is the aldehyde form of (+)-JQ1. (+)-JQ-1-aldehyde can be uesd as a precursor to synthesize PROTACs, which targets **BET bromodomains**.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

(+)-JQ1 PA

Cat. No.: HY-112789

(+)-JQ1 PA is a derivative of the Bromodomain and extra-terminal **(BET)** inhibitor JQ1, with an IC_{50} of 10.4 nM.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(2S,3R)-LP99

Cat. No.: HY-116227

(2S,3R)-LP99 is a potent and selective **BRD7** and **BRD9** inhibitor with an K_D of 99 nM for BRD9. (2S,3R)-LP99 inhibits the association of BRD7 and BRD9 to acetylated histones in vitro and in cells. (2S,3R)-LP99 demonstrates that BRD7/9 plays a role in regulating pro-inflammatory cytokine secretion.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E/Z)-ZL0420

Cat. No.: HY-112149A

(E/Z)-ZL0420 is a racemic compound of (Z)-ZL0420 and (E)-ZL0420 isomers. (E)-ZL0420 is a potent and selective bromodomain-containing protein 4 (**BRD4**) inhibitor with IC_{50} values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-(-)-JQ1 Enantiomer

Cat. No.: HY-13030A

(R)-(-)-JQ1 Enantiomer is the stereoisomer of (+)-JQ1. (+)-JQ1 potently decreases expression of both BRD4 target genes, whereas (R)-(-)-JQ1 Enantiomer has no effect.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

(R)-BAY1238097

Cat. No.: HY-112316A

(R)-BAY1238097 is the R-isomer with lower activity of BAY1238097.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(Rac)-BAY1238097

Cat. No.: HY-112316B

(Rac)-BAY1238097 is a **BET** inhibitor, with an IC_{50} of 1.02 μM for BRD4. Used in cancer research.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(S)-GNE-987

Cat. No.: HY-129937

(S)-GNE-987 (compound 4), the GNE-987 (a chimeric BET degrader) hydroxy-proline epimer, abrogates binding to **von Hippel-Lindau** and does not degrade **BRD4** protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-JQ-35
(TEN-010)

Cat. No.: HY-117286

(S)-JQ-35 (TEN-010) is an inhibitor of the Bromodomain and Extra-Terminal **(BET)** family bromodomain-containing proteins with potential antineoplastic activity.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

653-47

Cat. No.: HY-134598

653-47, a potentiator, significantly potentiates the cAMP-response element binding protein **(CREB)** inhibitory activity of 666-15. 653-47 is also a very weak CREB inhibitor with IC_{50} of 26.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

653-47 hydrochloride

Cat. No.: HY-134598A

653-47 hydrochloride, a potentiator, significantly potentiates the cAMP-response element binding protein **(CREB)** inhibitory activity of 666-15. 653-47 hydrochloride is also a very weak CREB inhibitor with IC_{50} of 26.3 μM.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

666-15

Cat. No.: HY-101120

666-15 is a potent and selective **CREB** inhibitor with an IC_{50} of 81 nM. 666-15 suppresses tumor growth in a breast cancer xenograft model.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

A-366

Cat. No.: HY-12583

A-366 is a potent, highly selective, peptide-competitive histone methyltransferase **G9a** inhibitor with IC_{50}s of 3.3 and 38 nM for G9a and GLP (EHMT1), respectively. A-366 shows >1000-fold selectivity over 21 other methyltransferases.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

A-485

Cat. No.: HY-107455

A-485 is a potent and selective catalytic inhibitor of **p300/CBP** with IC_{50}s of 9.8nM and 2.6nM for **p300** and **CBP** histone acetyltransferase (HAT), respectively.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

A1874

Cat. No.: HY-114305

A1874 is a nutlin-based (**MDM2** ligand) and **BRD4**-degrading PROTAC with a DC_{50} of 32 nM (induce BRD4 degradation in cells). Effective in inhibiting many cancer cell lines proliferation.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ABBV-744

Cat. No.: HY-112090

ABBV-744 is a first-in-class, orally active and selective inhibitor of the **BDII domain** of BET family proteins with IC_{50} values ranging from 4 to 18 nM for BRD2, BRD3, BRD4 and BRDT.



Purity: 99.97%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ACBI1

Cat. No.: HY-128359

ACBI1 is a potent **PROTAC** degrader of BAF ATPase subunits **SMARCA2** and **SMARCA4**, also degrades the polybromo-associated BAF (PBAF) complex member **PBRM1**, with DC_{50}s of 6 nM, 11 nM and 32 nM for SMARCA2, SMARCA4 and PBRM1 in MV-4-11 cells, respectively.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AGB1

Cat. No.: HY-145227

AGB1 is a fast, highly selective, and potent bump-and-hole (B&H)-**PROTAC** degrader for BromoTag. AGB1 exhibits degradation for Ab:$Brd4^{BD2\ L387A}$ and Ab: BromoTag-Brd2 with pDC_{50}s of 7.8 and 7.9. AGB1 exhibits binary affinity to **VHL** (K_d=125 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alobresib

(GS-5829)

Cat. No.: HY-109050

Alobresib (GS-5829) is a **BET bromodomain** inhibitor, which represents a highly effective therapeutics agent against recurrent/chemotherapy resistant uterine serous carcinoma (USC) overexpressing c-Myc.



Purity: 98.07%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Amredobresib

Cat. No.: HY-145550

Amredobresib is a potent inhibitor of **BET**. Amredobresib inhibits the binding of bromodomains to acetylated lysines on histone H3 and H4 and thus acts as important regulators of gene transcription.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anacardic Acid

(Hydroginkgolic acid; Ginkgolic Acid C15:0)

Cat. No.: HY-N2020

Anacardic Acid, extracted from cashew nut shell liquid, is a **histone acetyltransferase** inhibitor, inhibits HAT activity of p300 and PCAF, with IC_{50}s of 8.5 μM and 5 μM, respectively.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Apabetalone

(RVX-208; RVX000222)

Cat. No.: HY-16652

Apabetalone (RVX-208) is an inhibitor of **BET** transcriptional regulators with selectivity for the second bromodomain. The IC_{50}s are 87 μM and 0.51 μM for **BD1** and **BD2**, respectively.



Purity: 99.47%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ARV-771

Cat. No.: HY-100972

ARV-771 is a potent **BET** PROTAC based on E3 ligase **von Hippel-Lindau** with K_ds of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for **BRD2(1)**, **BRD2(2)**, **BRD3(1)**, **BRD3(2)**, **BRD4(1)**, and **BRD4(2)**, respectively.



Purity: 99.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

ARV-825

Cat. No.: HY-16954

ARV-825 is a PROTAC connected by ligands for **Cereblon** and **BRD4**. ARV-825 binds to BD1 and BD2 of BRD4 with K_ds of 90 and 28 nM, respectively.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AU-15330

Cat. No.: HY-145388

AU-15330 is a proteolysis-targeting chimera (PROTAC) degrader of the SWI/SNF ATPase subunits, **SMARCA2** and **SMARCA4**. AU-15330 induces potent inhibition of tumour growth in xenograft models of prostate cancer and synergizes with the AR antagonist enzalutamide.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZ13824374

Cat. No.: HY-136521

AZ13824374 is a highly potent and selective **ATAD2** bromodomain inhibitor which shows cellular target engagement and antiproliferative activity in a range of breast cancer models. AZ13824374 inhibits ATAD2 with pIC_{50}s of 8.2 and 6.2 in ATAD2 FRET assay and ATAD2 NanoBRET assay, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZD5153 6-Hydroxy-2-naphthoic acid

(AZD-5153 HNT salt)

Cat. No.: HY-100653A

AZD5153 6-Hydroxy-2-naphthoic acid is the 6-Hydroxy-2-naphthoic acid of AZD5153. AZD5153 is a potent, selective, and orally available **BET/BRD4** bromodomain inhibitor; disrupts BRD4 with an IC_{50} of 1.7 nM.



Purity: 99.95%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY-299

Cat. No.: HY-107424

BAY-299 is a very potent, dual inhibitor with IC_{50}s of 67 nM for **BRPF2 bromodomains (BD)**, 8 nM for **TAF1 BD2**, and 106 nM for **TAF1L BD2**.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY-850

Cat. No.: HY-119254

BAY-850 is a potent and isoform selective ATPase family AAA domain-containing protein 2 **(ATAD2)** inhibitor, with an IC_{50} of 166 nM.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY1238097

Cat. No.: HY-112316

BAY1238097 is a potent and selective inhibitor of **BET binding to histones** and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome (IC_{50} <100 nM).



Purity: 98.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BAZ1A-IN-1

Cat. No.: HY-141890

BAZ1A-IN-1 is a potent inhibitor of **BAZ1A** (bromodomain-containing protein). BAZ1A-IN-1 shows a K_D value of 0.52 μM against **BAZ1A** bromodomain.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

BAZ2-ICR

Cat. No.: HY-19336

BAZ2-ICR is a potent, selective, cell active and orally active **BAZ2A/B bromodomains** inhibitor with **IC_{50}**s of 130 nM and 180 nM, and **K_d**s of 109 nM and 170 nM, respectively.



Purity: 98.53%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 2 g

BET bromodomain inhibitor

Cat. No.: HY-103036

BET bromodomain inhibitor is a potent **BET** inhibitor extracted from patent WO/2015/153871A2, compound example 11.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BET bromodomain inhibitor 1

Cat. No.: HY-131061

BET bromodomain inhibitor 1 is an orally active, selective **bromodomain and extra-terminal (BET) bromodomain** inhibitor with an **IC_{50}** of 2.6 nM for BRD4.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BET bromodomain inhibitor 2

Cat. No.: HY-146709

BET bromodomain inhibitor 2 is a potent **BET bromodomain** inhibitor with an IC_{50} of 14.1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BET-BAY 002

Cat. No.: HY-12421

BET-BAY 002 is a potent BET inhibitor; shows efficacy in a multiple myeloma model.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BET-BAY 002 (S enantiomer)

Cat. No.: HY-12421B

BET-BAY 002 S enantiomer is the S-enantiomer of BET-BAY 002. BET-BAY 002 is a **BET** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg

BET-IN-1

Cat. No.: HY-115727

BET-IN-1 is a potent **BET** inhibitor that has excellent brain penetration and reasonable metabolic stability.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BET-IN-2

Cat. No.: HY-102044

BET-IN-2 is a **BET** inhibitor with an **IC_{50}** of 52 nM for BRD4-BD1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BET-IN-6

Cat. No.: HY-130813

BET-IN-6 is a potent and high affnity **BRD2/BRD4** inhibitor. BET-IN-6 is the **ligand** for target protein BRD2/4, and is used for the systhesis of PROTAC BRD2/BRD4 degrader-1 (HY-130612).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BETd-246

Cat. No.: HY-115568

BETd-246 is a second-generation and **PROTAC**-based **BET bromodomain (BRD)** inhibitor connected by ligands for **Cereblon** and **BET**, exhibiting superior selectivity, potency and antitumor activity.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

BETd-260

(ZBC 260)

Cat. No.: HY-101519

BETd-260 (ZBC 260) is a PROTAC connected by ligands for **Cereblon** and **BET**, with as low as 30 pM against **BRD4** protein in RS4;11 leukemia cell line. BETd-260 potently suppresses cell viability and robustly induces **apoptosis** in hepatocellular carcinoma (HCC) cells.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

BI 2536

Cat. No.: HY-50698

BI 2536 is a dual **PLK1** and **BRD4** inhibitor with IC_{50}s of 0.83 and 25 nM, respectively. BI-2536 suppresses IFNB (encoding IFN-β) gene transcription.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 25 mg, 50 mg, 100 mg

BI-7273

Cat. No.: HY-100351

BI-7273 is a selective, and cell-permeable **BRD9** inhibitor, with an IC_{50} and a K_d of 19 and 0.75 nM; also shows high effect on BRD7, with an IC_{50} and a K_d of 117 nM and 0.3 nM.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

BI-9564

Cat. No.: HY-100352

BI-9564 is a potent, selective and cell-permeable **BRD9/BRD7 bromodomains** inhibitor, with IC_{50}s of 75 nM and 3.4 μM and K_ds of 14 nM and 239 nM, respectively. BI-9564 has an IC_{50} of > 100 μM for BET family.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Biotinylated-JQ1

(Biotin-JQ1)

Cat. No.: HY-145667

Biotinylated-JQ1 (Biotin-JQ1) is a biotinylated derivative of JQ1 with high affinity for the bromodomain of **BRD4**. Biotinylated-JQ1 inhibits MM1.S multiple myeloma cells proliferation with the EC_{50} of 0.4 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Birabresib

(OTX-015; MK-8628)

Cat. No.: HY-15743

Birabresib (OTX-015) is a potent **bromodomain (BRD2/3/4)** inhibitor with IC_{50}s ranging from 92 to 112 nM.



Purity: 99.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

BMS-986158

Cat. No.: HY-101567

BMS-986158 is a potent **BET** inhibitor with IC_{50}s of 6.6 and 5nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respectively.



Purity: 99.95%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg

BPTF-IN-1

Cat. No.: HY-145431

BPTF-IN-1 (compound AU1) is a selective **bromodomain and PHD finger containing transcription factor (BPTF) bromodomain** inhibitor with a K_d of 2.8 μM. BPTF-IN-1 shows to be selective for BPTF over BRD4 bromodomain. BPTF-IN-1 shows antimalarial activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BPTF-IN-BZ1

Cat. No.: HY-132889

BPTF-IN-BZ1, a **BPTF** inhibitor, possesses a high potency (K_d = 6.3 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD-IN-3

Cat. No.: HY-128597

BRD-IN-3 ((R,R)-36n) is a highly potent **PCAF bromodomain (BRD)** inhibitor, with an IC_{50} of 7 nM. BRD-IN-3 also exhibits activity against GCN5 and FALZ.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD4 D1-IN-1

Cat. No.: HY-142704

BRD4 D1-IN-1 is a selective **BRD4 D1** inhibitor (IC_{50}<0.092 μM). BRD4 D1-IN-1 has 18 nM affinity against BRD4 D1 and over 500-fold selectivity against BRD2 D1 and BRD4 D2 via ITC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD4 D1-IN-2

Cat. No.: HY-142705

BRD4 D1-IN-2 (compound 26) is a potent and selective **BRD4 D1** inhibitor (IC_{50}<0.092 μM). BRD4 D1-IN-2 has 15 nM affinity against BRD4 D1 and over 500-fold selectivity against BRD2 D1 and BRD4 D2 via ITC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD4 degrader AT1

Cat. No.: HY-111433

BRD4 degrader AT1 is a PROTAC connected by ligands for **von Hippel-Lindau** and **BRD4** as a highly selective **Brd4** degrader, with a K_d of 44 nM for $Brd4^{BD2}$ in cells.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

BRD4 Inhibitor-10

Cat. No.: HY-117491

BRD4 Inhibitor-10 is a potent **BRD4-BD1** inhibitor extracted from patent WO2015022332A1, Compound II-25, has an IC_{50} of 8 nM.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BRD4 Inhibitor-16

Cat. No.: HY-115926

BRD4 Inhibitor-16 (Compound 4) is a potent inhibitor of bromodomain 4 (**BRD4**). Overexpression of bromodomain 4 (BRD4) is closely correlated with a variety of human cancers by regulating the histone post-translational modifications.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD4 Inhibitor-17

Cat. No.: HY-145909

BRD4 Inhibitor-17 (Compound 5i) is a potent inhibitor of **BRD4** with an IC_{50} of 0.33 μM. BRD4 Inhibitor-17 plays crucial role in regulating transcription of inflammatory, proliferation and cell cycle genes. BRD4 Inhibitor-17 serves as potential antidotes for arsenicals.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD4 Inhibitor-18

Cat. No.: HY-146660

BRD4 Inhibitor-18 is a highly potent **BRD4** inhibitor with an IC_{50} value of 110 nM. BRD4 Inhibitor-18 has a hydrophobic acetylcyclopentanyl side chain. BRD4 Inhibitor-18 can significantly suppress the proliferation of MV-4-11 cells with high BRD4 level.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD4 Inhibitor-19

Cat. No.: HY-146739

BRD4 Inhibitor-19 is a **BET** inhibitor with an IC_{50} of 55 nM for BRD4-BD1. BRD4 Inhibitor-19 can be used for multiple myeloma research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD4-BD1/2-IN-1

Cat. No.: HY-142674

BRD4-BD1/2-IN-1 is a potent **BRD4** inhibitor with IC_{50}s of <100 nM for BRD4 BD-1 and BRD4 BD-2, respectively (US20150148375A1, compound 5).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD4-BD1/2-IN-2

Cat. No.: HY-142675

BRD4-BD1/2-IN-2 is a potent **BRD4 BD2** inhibitor with **IC_{50}**s of <0.5 nM and <300 nM for BRD4 BD2 and BRD4 BD1, respectively (WO2021233371A1, compound 2).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD4-IN-2

Cat. No.: HY-141843

BRD4-IN-2 is a bromodomain **BRD4** inhibitor with an **IC_{50}** value of 9.9 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD4/CK2-IN-1

Cat. No.: HY-145260

BRD4/CK2-IN-1 is the first highly effective and oral active dual-target inhibitor of **BRD4/CK2** (bromodomain-containing protein 4/casein kinase 2), with **IC_{50}**s of 180 nM and 230 nM for BRD4 and CK2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD7-IN-1

Cat. No.: HY-111905

BRD7-IN-1, a modified derivative of BI7273 (BRD7/9 inhibitor), binds to a VHL ligand via a linker to form a **PROTAC** VZ185 (VZ185 against BRD7/9 with DC_{50}s of 4.5 and 1.8 nM, respectively).



Purity: 98.28%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

BRD7-IN-1 free base

Cat. No.: HY-111905A

BRD7-IN-1 free base, a modified derivative of BI7273 (BRD7/9 inhibitor), binds to a VHL ligand via a linker to form a **PROTAC** VZ185 (VZ185 against BRD7/9 with DC_{50}s of 4.5 and 1.8 nM, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRM/BRG1 ATP Inhibitor-1

Cat. No.: HY-119374

BRM/BRG1 ATP Inhibitor-1 is an allosteric dual brahma homolog **(BRM)**/SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily A member 2 **(SMARCA2)** and brahma related gene 1 **(BRG1)/SMARCA4** ATPase activity inhibitor, both **IC_{50}**s are below 0.005 μM.



Purity: 98.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

BRM/BRG1 ATP Inhibitor-2

Cat. No.: HY-145946

BRM/BRG1 ATP Inhibitor-2 is a **BRG1/BRM ATPase** inhibitor for the treatment of BAF-related disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bromodomain IN-1

Cat. No.: HY-116349

Bromodomain IN-1 is a **Bromodomain** inhibitor extracted from patent WO2016069578A1, compound 4 .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bromodomain inhibitor-8

Cat. No.: HY-128703

Bromodomain inhibitor-8 (Intermediate 21) is a **BET bromodomain** inhibitor for treating autoimmune and inflammatory diseases.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bromosporine

Cat. No.: HY-15815

Bromosporine is a broad spectrum inhibitor for bromodomains with IC50 of 0.41 μM, 0.29 μM, 0.122 μM and 0.017 μM for BRD2, BRD4, BRD9 and CECR2, respectively.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BY27

Cat. No.: HY-126325

BY27 is a potent and selective **BET BD2** inhibitor, shows 38, 5, 7, and 21-fold BD1/BD2 selectivity for BRD2, BRD3, BRD4, and BRDT. Anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

C646

Cat. No.: HY-13823

C646 is a selective and competitive **histone acetyltransferase p300** inhibitor with K_i of 400 nM, and is less potent for other acetyltransferases.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

CBP/p300-IN-1

Cat. No.: HY-111420

CBP/p300-IN-1 is a **CBP/EP300** bromodomain inhibitor.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CBP/p300-IN-12

Cat. No.: HY-132197

CBP/p300-IN-12 is a potent and selective covalent **histone acetyltransferases p300** (IC_{50} of 166 nM) and **CBP** inhibitor. CBP/p300-IN-12 decreases the levels of H3K27Ac of PC-3 cells (EC_{50} of 37 nM). CBP/p300-IN-12 forms a covalent adduct with C1450.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

CBP/p300-IN-14

Cat. No.: HY-139861

CBP/p300-IN-14 is a potent inhibitor of **CBP/EP300** (lysine acetyltransferase) with an IC_{50} of 3.3 nM (extracted from patent WO2021213521A1, compound 27).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CBP/p300-IN-2

Cat. No.: HY-128761

CBP/EP300-IN-2 is an inhibitor of **CBP/EP300** with IC_{50} values of 1.07 nM and 5.96 nM for CBP/HTRF and Myc, respectively. CBP/EP300-IN-2, example 25, is extracted from patent WO2017205538A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CBP/p300-IN-8

Cat. No.: HY-136920

CBP/p300-IN-8 is a potent inhibitor of the **CBP/P300 family of bromodomains**. CBP/p300-IN-8 inhibits CBP (IC_{50}=0.01-0.1 μM) and BRD4 (IC_{50}=1-1000 μM) activity.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

CD161

(NKR-P1A)

Cat. No.: HY-124596

CD161 (NKR-P1A) is a potent, selective and orally bioavailable **bromodomain and extra-terminal (BET) bromodomain** inhibitor with an IC_{50}s of 28.2 nM and 7.2 nM for BRD4 BD1 and BRD4 BD2, respectively. CD161 has good anticancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CD235

Cat. No.: HY-128977

CD235 is a structurally similar analogue of CD161. CD161 is a potent and orally bioavailable **BET** bromodomain inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CEM114

Cat. No.: HY-136572

CEM114 is an effective chemical **epigenetic** modifier (CEM) that recruits endogenous chromatin machinery through CRISPR-Cas9 systems.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CeMMEC1

Cat. No.: HY-111445

CeMMEC1 is an inhibitor of **BRD4**, and also has high affinity for **TAF1**, with an IC_{50} of 0.9 μM for TAF1, and a K_d of 1.8 μM for TAF1 (2).



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CF53

Cat. No.: HY-112610

CF53 is a highly potent, selective and orally active inhibitor of **BET** protein, with a K_i of <1 nM, K_d of 2.2 nM and an IC_{50} of 2 nM for BRD4 BD1.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CFT8634

Cat. No.: HY-145925B

CFT8634 is a degrader targeting **BRD9** extracted from patent WO2021178920A1 compound 173. CFT8634 can be used for the research of synovial sarcoma and SMARCB1-deleted solid tumors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CPI-169 racemate

Cat. No.: HY-15956

CPI-169 racemate is the racemate of CPI-169. CPI-169 is a novel and potent **EZH2** inhibitor.



Purity: 98.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CPI-203

Cat. No.: HY-15846

CPI-203 is a novel potent, selective and cell permeable inhibitor of **BET bromodomain**, with an IC_{50} value of appr 37 nM (BRD4 α-screen assay).



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

CPI-637

Cat. No.: HY-100482

CPI-637 is a selective and potent **CBP/EP300** bromodomain inhibitor with IC_{50} values of 0.03 μM, 0.051 μM and 11.0 μM for **CBP**, **EP300** and **BRD4 BD-1**, respectively, and an EC_{50} of 0.3 μM for **CBP**.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CREB-IN-1 TFA

Cat. No.: HY-144318

CREB-IN-1 TFA is a potent, orally active **CREB** inhibitor (IC_{50}=0.18 μM). CREB-IN-1 TFA inhibits breast cancer cell growth.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Curcumin

(Diferuloylmethane; Natural Yellow 3; Turmeric yellow)

Cat. No.: HY-N0005

Curcumin (Diferuloylmethane), a natural phenolic compound, is a **p300/CREB-binding protein-specific** inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription.



Purity: ≥96.0%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg, 500 mg

Curcumin-d6 (Diferuloylmethane-d6; Natural Yellow 3-d6; Turmeric yellow-d6)

Cat. No.: HY-N0005S

Curcumin D6 (Diferuloylmethane D6) is a deuterium labeled Curcumin (Turmeric yellow). Curcumin (Turmeric yellow) is a natural phenolic compound with diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

dBET1

Cat. No.: HY-101838

dBET1 is a PROTAC connected by ligands for **Cereblon** and **BRD4** with an EC_{50} of 430 nM. dBET1 is a PROTAC that composes of (+)-JQ1 (HY-13030) linked to NSC 527179 (HY-14658) with a linker.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

dBET23

Cat. No.: HY-123911

dBET23 is a highly effective and selective PROTAC **BRD4** degrader with a $DC_{50/5h}$ of ~ 50 nM for $BRD4_{BD1}$ protein.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

dBET57

Cat. No.: HY-123844

dBET57 is a potent and selective degrader of $BRD4_{BD1}$ based on the **PROTAC** technology. dBET57 mediates recruitment to the $CRL4^{Cereblon}$ E3 ubiquitin ligase, with a $DC_{50/5h}$ of 500 nM for $BRD4_{BD1}$, and is inactive on $BRD4_{BD2}$.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

dBET6

Cat. No.: HY-112588

dBET6 is a highly potent, selective and cell-permeable PROTAC connected by ligands for **Cereblon** and **BET**, with an IC_{50} of 14 nM, and has antitumor activity.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

dCBP-1

Cat. No.: HY-134582

dCBP-1 is a potent and selective heterobifunctional degrader of **p300/CBP** based on **Cereblon** ligand. dCBP-1 is exceptionally potent at killing multiple myeloma cells and ablates oncogenic enhancer activity driving MYC expression.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

dTRIM24

Cat. No.: HY-111519

dTRIM24 is a selective bifunctional degrader of **TRIM24** based on **PROTAC**, consists of ligands for **von Hippel-Lindau** and **TRIM24**.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

E-7386

Cat. No.: HY-111386

E-7386 is an orally active **CBP/beta-catenin** modulator.



Purity: 99.70%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

EML 425

Cat. No.: HY-110263

EML425 is a potent and selective CREB binding protein (**CBP**)/**p300** inhibitor with IC_{50}s of 2.9 and 1.1 μM, respectively.



Purity: 98.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

FHD-286

Cat. No.: HY-144835

FHD-286 is a **BRG1/BRM ATPase** inhibitor for the treatment of BAF-related disorders such as acute myeloid leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FHT-1015

Cat. No.: HY-144896

FHT-1205 is a potent **SMARCA4/SMARCA2 ATPase** (BRG1 and BRM) inhibitor with IC_{50}s of ≤10 nM (WO2020160180A1; compound 67).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FHT-1204

Cat. No.: HY-144897

FHT-1204 is a potent **SMARCA4/SMARCA2 ATPase** (BRG1 and BRM) inhibitor with **IC_{50}**s of ≤10 nM (WO2020160180A1; compound 70).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

FKBP12 PROTAC dTAG-7

(dTAG-7)

Cat. No.: HY-123941

FKBP12 PROTAC dTAG-7 (dTAG-7) is a heterobifunctional degrader. FKBP12 PROTAC dTAG-7 (dTAG-7) is a degrader of **$FKBP12^{F36V}$** with expression of $FKBP12^{F36V}$ in-frame with a protein of interest.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 5 mg

FL-411

(BRD4-IN-1)

Cat. No.: HY-111102

FL-411 is a potent and selective **BRD4** inhibitor with an **IC_{50}** of 0.43±0.09 μM for **BRD4(1)**.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GNE-049

Cat. No.: HY-108435

GNE-049 is a highly potent and selective **CBP** inhibitor with an **IC_{50}** of 1.1 nM in TR-FRET assay. GNE-049 also inhibits **BRET** and **BRD4(1)** with **IC_{50}**s of 12 nM and 4200 nM, respectively.



Purity: 98.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GNE-207

Cat. No.: HY-120028

GNE-207 is a potent, selective and orally bioavailable inhibitor of the bromodomain of **CBP**, with an **IC_{50}** of 1 nM, exhibits a selectively index of >2500-fold against BRD4 (1). GNE-207 shows excellent CBP potency, with an **EC_{50}** of 18 nM for MYC expression in MV-4-11 cells.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

GNE-272

Cat. No.: HY-100726

GNE-272 is a potent and selective **CBP/EP300** inhibitor with **IC_{50}** values of 0.02, 0.03 and 13 μM for CBP, EP300 and BRD4, respectively. GNE-272 is also a selective in vivo probe for CBP/EP300.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

GNE-375

Cat. No.: HY-123621

GNE-375 is a potent and highly selective **BRD9** inhibitor with an **IC_{50}** of 5 nM. GNE-375 shows >100-fold selective for BRD9 over BRD4, TAF1, and CECR2. GNE-375 decreases BRD9 binding to chromatin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GNE-781

Cat. No.: HY-108696

GNE-781 is an orally active, highly potent and selective **CBP** inhibitor with an **IC_{50}** of 0.94 nM in TR-FRET assay. GNE-781 also inhibits **BRET** and **BRD4(1)** with **IC_{50}**s of 6.2 nM and 5100 nM, respectively. GNE-781 displays antitumor activity in an MOLM-16 AML xenograft model.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GNE-987

Cat. No.: HY-129937A

GNE-987 is a PROTAC connected by ligands for **von Hippel-Lindau** and **BRD4**. GNE-987 exhibits picomolar cell **BRD4** degradation activity (**DC_{50}**=0.03 nM for EOL-1 AML cell line).



Purity: 98.90%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

GS-626510

Cat. No.: HY-114416

GS-626510 is a potent, and orally active **BET family bromodomains** inhibitor, with **K_d** values of 0.59-3.2 nM for BRD2/3/4, with **IC_{50}** values of 83 nM and 78 nM foe BD1 and BD2, respectively.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK 4027

Cat. No.: HY-101027

GSK 4027 is a chemical probe for the **PCAF/GCN5 bromodomain** with an **pIC$_{50}$** of 7.4±0.11 for PCAF in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK-5959

Cat. No.: HY-18665

GSK-5959 is a potent, selective and cell permeable **BRPF1** bromodomain inhibitor with an **IC$_{50}$** of ~ 80 nM.



Purity: 98.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GSK040

Cat. No.: HY-132230

GSK040 is a potent and highly selective **BET BD2** inhibitor, with a **pIC$_{50}$** of 8.3. GSK040 shows more than 5000-fold selectivity for BET BD2 over BET BD1 (pIC$_{50}$=4.6). GSK040 can be used for the research of oncology and immunology diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK046

(iBET-BD2)

Cat. No.: HY-136571

GSK046 (iBET-BD2) is a potent, selective and orally active **BD2 bromodomain** inhibitor of the **BET** proteins, with **IC$_{50}$**s of 264 nM (**BRD2 BD2**), 98 nM (**BRD3 BD2**), 49 nM (**BRD4 BD2**) and 214 nM (**BRDT BD2**), respectively. GSK046 has immunomodulatory activity.



Purity: 98.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK097

Cat. No.: HY-132232

GSK097 is a potent and selective Inhibitor of the second bromodomain (BD2) of the bromodomain and extra-terminal domain (BET) proteins. GSK097 displays 2000-fold selective for BD2 over BD1 (BRD4 data) with >1 mg/mL solubility in FaSSIF media.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK1324726A

(I-BET726)

Cat. No.: HY-13960

GSK1324726A is a novel, potent, and selective inhibitor of **BET** proteins with high affinity to **BRD2** (**IC$_{50}$**=41 nM), **BRD3** (**IC$_{50}$**=31 nM), and **BRD4** (**IC$_{50}$**=22 nM).



Purity: 98.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK1379725A

Cat. No.: HY-112398

GSK1379725A is a selective **BPTF** ligand with a K$_d$ of 2.8 uM, showing no binding activity for Brd4.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GSK232

Cat. No.: HY-145347

GSK232 is a highly selective, cellularly penetrant **CECR2** inhibitor with excellent physicochemical properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK2801

Cat. No.: HY-15658

GSK2801 is a potent, selective, orally active and cell active acetyl-lysine competitive **BAZ2A** and **BAZ2B** bromodomains inhibitor with K$_d$ values of 136 nM and 257 nM, respectively. GSK2801 shows >50-fold selectivity for **BAZ2A/B** over BRD4.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GSK4028

Cat. No.: HY-101027A

GSK4028 is the enantiomeric negative control of GSK4027, which is a PCAF/GCN5 bromodomain chemical probe, the **pIC$_{50}$** of GSK4028 is 4.9 in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.



Purity: 98.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK620

Cat. No.: HY-137892



GSK620 is a potent and orally active **pan-BD2** inhibitor with excellent broad selectivity, developability and in vivo oral pharmacokinetics. GSK620 is highly selective for the BET-BD2 family of proteins, with >200-fold selectivity over all other bromodomains.

Purity: 99.86%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK6853

Cat. No.: HY-100220



GSK6853 is a potent and selective inhibitor of the **BRPF1** bromodomain. GSK6853 shows excellent BRPF1 potency (pK_d=9.5) and greater than 1600-fold selectivity over all other bromodomains.

Purity: 99.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

GSK778

(iBET-BD1)

Cat. No.: HY-136570



GSK778 (iBET-BD1) is a potent and selective **BD1 bromodomain** inhibitor of the BET proteins, with IC_{50}s of 75 nM (**BRD2 BD1**), 41 nM (**BRD3 BD1**), 41 nM (**BRD4 BD1**), and 143 nM (**BRDT BD1**), respectively. GSK778 phenocopies the effects of pan-**BET** inhibitors in cancer models.

Purity: 99.25%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK852

Cat. No.: HY-115867



GSK852 is a highly potent, second bromodomain (BD2)-selective, **bromo and extra-terminal domain (BET)** inhibitor (pIC_{50} = 7.9).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK8573

Cat. No.: HY-107477



GSK8573 (compound 23) is an inactive control compound for GSK2801. GSK8573 has binding activity to **BRD9** with a K_d value of 1.04 μM and is inactive against BAZ2A/B and other bromodomain familiy.

Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

GSK8814

Cat. No.: HY-114204



GSK8814 is a potent, selective, and **ATAD2/2B bromodomain** chemical probe and inhibitor, with a binding constant pK_d=8.1 and a pK_i=8.9 in BROMOscan. GSK8814 binds to ATAD2 and BRD4 BD1 with pIC_{50}s of 7.3 and 4.6, respectively.

Purity: 98.65%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

GSK9311

Cat. No.: HY-100729



GSK9311, a less active analogue of GSK6853, can be used as a negative control. GSK9311 inhibits **BRPF bromodomain** with pIC_{50} values of 6.0 and 4.3 for BRPF1 and BRPF2, respectively.

Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK9311 hydrochloride

Cat. No.: HY-100729A



GSK9311 hydrochloride, a less active analogue of GSK6853, can be used as a negative control. GSK9311 hydrochloride inhibits **BRPF bromodomain** with pIC_{50} values of 6.0 and 4.3 for BRPF1 and BRPF2, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK973

Cat. No.: HY-138563



GSK973 is a highly selective, orally bioavailable inhibitor of the **BD2s** (second bromodomains) of the BET family, with a pIC_{50} of 7.8 and a pK_d of 8.7 for BRD4 BD2. GSK973 displays a 1600-fold selectivity for BRD4 BD2 over BRD4 BD1.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HJB97

Cat. No.: HY-112429



HJB97 is a high-affinity **BET** inhibitor with K_is of 0.9 nM (**BRD2 BD1**), 0.27 nM (**BRD2 BD2**), 0.18 nM (**BRD3 BD1**), 0.21 nM (**BRD3 BD2**), 0.5 nM (**BRD4 BD1**), 1.0 nM (**BRD4 BD2**), respectively. HJB97 is employed for the design of potential **PROTAC BET** degrader and has antitumor activity.

Purity: 98.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

I-BET151

(GSK1210151A)

Cat. No.: HY-13235

I-BET151 (GSK1210151A) is a **BET bromodomain** inhibitor which inhibits **BRD4**, **BRD2**, and **BRD3** with **pIC$_{50}$** of 6.1, 6.3, and 6.6, respectively.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

I-BET151 dihydrochloride

(GSK1210151A dihydrochloride)

Cat. No.: HY-110106

I-BET151 dihydrochloride (GSK1210151A dihydrochloride) is a **BET bromodomain** inhibitor which inhibits **BRD4**, **BRD2**, and **BRD3** with **pIC$_{50}$** of 6.1, 6.3, and 6.6, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

I-BET282

Cat. No.: HY-19760

I-BET282 is a pan-inhibitor of all eight **BET bromodomains**, and selectivity over other representative bromodomain-containing proteins. I-BET282 shows pIC$_{50}$s ranging 6.4-7.7 for BRD2 (BD1/BD2), BRD2 (BD1/BD), BRD3 (BD1/BD), and BRD4 (BD1/BD).



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

I-BET282E

Cat. No.: HY-19760B

I-BET282E is a pan-inhibitor of all eight **BET bromodomains**, and selectivity over other representative bromodomain-containing proteins. I-BET282E shows pIC$_{50}$s ranging 6.4-7.7 for BRD2 (BD1/BD2), BRD2 (BD1/BD), BRD3 (BD1/BD), and BRD4 (BD1/BD).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

I-BET567

Cat. No.: HY-142520

I-BET567 is a potent and orally active inhibitor of **pan-BET** candidate with **pIC$_{50}$**s of 6.9 and 7.2 for BRD4 BD1 and BD2, respectively. I-BET567 has been demonstrated efficacy in mouse models of oncology and inflammation.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

I-BET762 carboxylic acid (Molibresib carboxylic acid; GSK525762A carboxylic acid; PROTAC BRD4-binding moiety 2)

Cat. No.: HY-107443

I-BET762 carboxylic acid (Molibresib carboxylic acid) is an I-BET762-based warhead ligand for conjugation reactions of PROTAC targeting on BET. I-BET762 carboxylic acid (Molibresib carboxylic acid) is a **BRD4** inhibitor with a **pIC$_{50}$** of 5.1.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

I-BRD9

Cat. No.: HY-18975

I-BRD9 is the first selective cellular chemical probe for BRD9 (pIC50=7.3). IC50 value: 7.3 (pIC50) Target: BRD9 in vitro: I-BRD9 is a selective cell active chemical probe for bromodomain containing protein 9 inhibition.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

I-CBP112

Cat. No.: HY-19541

I-CBP112 is a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, that inhibits the **CBP/p300** bromodomains, enhances acetylation by p300.



Purity: 98.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

I-CBP112 hydrochloride

Cat. No.: HY-19541A

I-CBP112 hydrochloride is a selective inhibitor of **CBP/P300** that directly binds their bromodomains (K_ds = 142 and 625 nM, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IACS-9571

(ASIS-P040)

Cat. No.: HY-102000

IACS-9571 is a potent and selective inhibitor of **TRIM24** and **BRPF1**, with **IC$_{50}$** of 8 nM for TRIM24, and **K$_d$**s of 31 nM and 14 nM for TRIM24 and BRPF1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IACS-9571 hydrochloride

(ASIS-P040 hydrochloride) Cat. No.: HY-102000B

IACS-9571 (ASIS-P040) hydrochloride is a potent and selective inhibitor of **TRIM24** and **BRPF1**, with an IC_{50} of 8 nM for TRIM24, and K_ds of 31 nM and 14 nM for TRIM24 and BRPF1, respectively.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

INCB-057643

Cat. No.: HY-111485

INCB-057643 is a novel, orally bioavailable **BET** inhibitor.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

INCB054329

Cat. No.: HY-112504

INCB054329 is a potent **BET** inhibitor.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

INCB054329 Racemate

Cat. No.: HY-112504A

INCB054329 Racemate is a **BET** protein inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Inobrodib

(CCS1477) Cat. No.: HY-111784

Inobrodib (CCS1477) is an orally active, potent, and selective inhibitor of the **p300/CBP bromodomain**. Inobrodib binds to p300 and CBP with K_d values of 1.3 and 1.7 nM, respectively, and with 170/130-fold selectivity compared with BRD4 with a K_d of 222 nM.



Purity: 99.53%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

JQ-1 (carboxylic acid)

Cat. No.: HY-78695

JQ-1 carboxylic acid is a (+)-JQ1 derivative (a BET bromodomain inhibitor). JQ-1 carboxylic acid can be used as a precursor to synthesize PROTACs, which targets **BET bromodomains**.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

KB02-JQ1

Cat. No.: HY-129917

KB02-JQ1 is a highly selective and PROTAC-based **BRD4** degrader (molecular glue), but does not degrade BRD2 or BRD3. KB02-JQ1 promotes **BRD4** degradation by covalently modifying **DCAF16** (E3 ligase) and can improve the durability of protein degradation in biological systems.



Purity: 98.29%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

KG-501

(Naphthol AS-E phosphate) Cat. No.: HY-103299

KG-501 is a **CREB** inhibitor, with an IC_{50} of 6.89 μM.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

L-Moses

(L-45) Cat. No.: HY-101125

L-Moses (L-45) is the first potent, selective, and cell-active p300/CBP-associated factor (**PCAF**) bromodomain (**Brd**) inhibitor with a K_d of 126 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

L-Moses dihydrochloride

(L-45 dihydrochloride) Cat. No.: HY-101125A

L-Moses (L-45) dihydrochloride is the first potent, selective, and cell-active p300/CBP-associated factor (**PCAF**) bromodomain (**Brd**) inhibitor with a K_d of 126 nM.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

LP99

Cat. No.: HY-19553

LP99, an epigenetic probe, is a potent and selective inhibitor of the **BRD7** and **BRD9** bromodomains with a K_d of 99 nM against BRD9. LP99 disrupts the binding of BRD7 and BRD9 to chromatin in cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

LT052

Cat. No.: HY-130622

LT052 is a highly selective **BET BD1** inhibitor with an **IC_{50}** of 87.7 nM. LT052 exhibits nanomolar BRD4 BD1 potency and 138-fold selectivity over BRD4 BD2 (IC_{50}=12.130 μM). LT052 has anti-inflammatory activity and can be used for acute gout arthritis research.



Purity: 98.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

M-1211

Cat. No.: HY-132234

M1121 is a covalent and orally active inhibitor of the menin-MLL interaction capable of achieving complete and persistent tumor regression.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

M-525

Cat. No.: HY-124069

M-525 is a first-in-class, highly potent, irreversible and covalent **menin-MLL** protein-protein interaction inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

M-808

Cat. No.: HY-133738

M-808 is a highly potent and efficacious covalent **Menin-MLL** interaction inhibitor, with a binding **IC_{50}** value of 2.6 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Menin-MLL inhibitor 19

Cat. No.: HY-139076

Menin-MLL inhibitor 19, a potent exo-aza spiro inhibitor of **menin-mll interaction**, example A17, extracted from patent WO2019120209A1. Menin-MLL inhibitor 19 can be used for the reseaech of various diseases, such as cancer, myelodysplastic syndrome (MDS) and diabetes.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Menin-MLL inhibitor 20

Cat. No.: HY-128798

Menin-MLL inhibitor 20 is an irreversible **menin-MLL interaction** inhibitor with antitumor activities (WO2020142557A1, compound 6).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Menin-MLL inhibitor 4

Cat. No.: HY-129167

Menin-MLL inhibitor 4 is an inhibitor of **Menin-MLL (mixed-lineage leukemia protein) interaction** extracted from patent WO2017214367, compound example 1. Menin-MLL inhibitor 4 has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Menin-MLL inhibitor MI-2

Cat. No.: HY-15222

Menin-MLL inhibitor MI-2 is a **Menin-MLL** interaction inhibitor with **IC_{50}** of 446±28 nM.



Purity: 99.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

MG 149

(Tip60 HAT inhibitor)

Cat. No.: HY-15887

MG149 (Tip60 HAT inhibitor) is a selective and potent **Tip60** inhibitor with **IC_{50}** of 74 uM, similar potentcy for **MOF** (**IC_{50}**= 47 uM); little potent for PCAF and p300 (IC_{50} >200 uM).



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MI-1

Cat. No.: HY-111937

MI-1 inhibits **Menin-MLL** interaction with an IC_{50} of 1.9 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MI-136

Cat. No.: HY-19319

MI-136 is an inhibitor of the **menin-MLL protein-protein** interaction (PPI), with an IC_{50} of 31 nM and a K_d of 23.6 nM. MI-136 shows to block AR signaling and has the potential for the study in castration-resistant tumors.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MI-2-2

Cat. No.: HY-108350

MI-2-2 is a potent menin-MLL inhibitor. MI-2-2 binds to menin with low nanomolar affinity (K_d=22nM) and very effectively disrupts the bivalent protein-protein interaction between menin and MLL.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

MI-3

(Menin-MLL inhibitor 3)

Cat. No.: HY-15223

MI-3 (Menin-MLL inhibitor 3) is a potent and high affinity **menin-MLL** inhibitor with an IC_{50} of 648 nM and a K_d of 201 nM.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MI-3454

Cat. No.: HY-136360

MI-3454 is an orally active, highly potent and selective **menin-MLL1 interaction** inhibitor with an IC_{50} of 0.51 nM.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MI-463

Cat. No.: HY-19809

MI-463 is a highly potent and orally bioavailable small molecule inhibitor of the **menin-mLL** interaction.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

MI-503

Cat. No.: HY-16925

MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the **menin-mLL** interaction.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

MI-538

Cat. No.: HY-19810

MI-538 is an inhibitor of the interaction between **menin** and **MLL** fusion proteins with an IC_{50} of 21 nM.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Mivebresib

(ABBV-075)

Cat. No.: HY-100015

Mivebresib (ABBV-075) is a potent and orally active **bromodomain and extraterminal domain (BET) bromodomain** inhibitor. Mivebresib binds to **BRD4** with a K_i of 1.5 nM.



Purity: 99.42%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Molibresib

(I-BET762; GSK525762; GSK525762A)

Cat. No.: HY-13032

Molibresib (I-BET762; GSK525762) is a **BET bromodomain** inhibitor with IC_{50} of 32.5-42.5 nM.



Purity: 99.85%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Molibresib besylate

(GSK 525762C; I-BET 762 besylate)

Cat. No.: HY-13032B

Molibresib besylate (GSK 525762C; I-BET 762 besylate) is a **BET bromodomain** inhibitor with **IC_{50}** of 32.5-42.5 nM.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

MS31

Cat. No.: HY-125837

MS31 is a potent, highly affinity and selective fragment-like methyllysine reader protein **spindlin 1 (SPIN1)** inhibitor. MS31 potently inhibits the interactions between SPIN1 and H3K4me3 (**IC_{50}**=77 nM, AlphaLISA; 243 nM, FP). MS31 selectively binds Tudor domain II of SPIN1 (**K_d**=91 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

MS31 trihydrochloride

Cat. No.: HY-125837A

MS31 trihydrochloride is a potent, highly affinity and selective fragment-like methyllysine reader protein **spindlin 1 (SPIN1)** inhibitor. MS31 trihydrochloride potently inhibits the interactions between SPIN1 and H3K4me3 (**IC_{50}**=77 nM, AlphaLISA; 243 nM, FP).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MS402

Cat. No.: HY-120000

MS402 is a **BD1**-selective **BET BrD** inhibitor with **K_i**s of 77 nM, 718 nM, 110 nM, 200 nM, 83 nM, and 240 nM for **BRD4(BD1)**, **BRD4(BD2)**, **BRD3(BD1)**, **BRD3(BD2)**, **BRD2(BD1)** and **BRD2(BD2)**, respectively. MS402 blocks Th17 cell differentiation and ameliorates colitis in mice.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MS417

(GTPL7512)

Cat. No.: HY-111139

MS417 is a selective BET-specific **BRD4** inhibitor, binds to BRD4-BD1 and BRD4-BD2 with **IC_{50}**s of 30, 46 nM and **K_d**s of 36.1, 25.4 nM, respectively, with weak selectivity at CBP BRD (**IC_{50}**, 32.7 μM).



Purity: 99.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

MS436

Cat. No.: HY-13959

MS436 is a new class of **bromodomain** inhibitor, exhibits potent affinity of an estimated **K_i**=30-50 nM for the BRD4 BrD1 and a 10-fold selectivity over the BrD2.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MS645

Cat. No.: HY-125232

MS645 is a bivalent **BET bromodomains (BrD)** inhibitor with a K_i of 18.4 nM for BRD4-BD1/BD2. MS645 spatially constrains bivalent inhibition of BRD4 BrDs resulting in a sustained repression of BRD4 transcriptional activity in solid-tumor cells.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MT1

Cat. No.: HY-111976

MT1 is a bivalent chemical probe of **BET bromodomains**, with an **IC_{50}** of 0.789 nM for BRD4(1).
.



Purity: 98.37%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MZ 1

Cat. No.: HY-107425

MZ 1 is a PROTAC connected by ligands for **von Hippel-Lindau** and **BRD4**. MZ 1 potently and rapidly induces reversible, long-lasting, and selective removal of BRD4 over BRD2 and BRD3. **K_d**s of 382/120, 119/115, and 307/228 nM for **BRD4 BD1/2**, BRD3 BD1/2, and BRD2 BD1/2, respectively.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg

MZP-54

Cat. No.: HY-112376

MZP-54 is a PROTAC connected by ligands for **von Hippel-Lindau** and **BRD3/4**, with a **K_d** of 4 nM for $Brd4^{BD2}$.

Purity: 98.16%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

MZP-55

Cat. No.: HY-112377

MZP-55 is a PROTAC connected by ligands for **von Hippel-Lindau** and **BRD3/4**, with a K_d of 8 nM for Brd4^{BD2}.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

M89

Cat. No.: HY-128347

M-89 is a highly potent and specific **menin** inhibitor, with a K_d of 1.4 nM for binding to menin. M-89 inhibits the **menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction** and has potential to treat MLL leukemia.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Naphthol AS-E

Cat. No.: HY-104068

Naphthol AS-E is a potent and cell-permeable inhibitor of **KIX-KID interaction**. Naphthol AS-E directly binds to the KIX domain of CBP (K_d:8.6 μM), blocks the interaction between the KIX domain and the KID domain of CREB with IC_{50} of 2.26 μM. Naphthol AS-E can be used for cancer research.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

NEO2734

(EP31670)

Cat. No.: HY-136938

NEO2734 (EP31670) is an orally active dual **p300/CBP** and **BET bromodomain** selective inhibitor, with IC_{50} values of <30 nM for both p300/CBP and BET bromodomains. NEO2734 is active in SPOP mutant and wild-type prostate cancer.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NHWD-870

Cat. No.: HY-134463

NHWD-870 is a potent, orally active and selective **BET family bromodomain** inhibitor and only binds bromodomains of BRD2, BRD3, BRD4 (IC_{50}=2.7 nM), and BRDT. NHWD-870 has potent tumor suppressive efficacies and suppresses cancer cell-macrophage interaction.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NI-42

Cat. No.: HY-101121

NI-42 (compound 13-d), a structurally orthogonal chemical probe for the BRPFs, is a biased, potent inhibitor of the **BRD of the BRPFs** (IC_{50}s of BRPF1/2/3=7.9/48/260 nM; K_ds of BRPF1/2/3=40/210/940 nM) with excellent selectivity over nonclass IV BRD proteins.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NI-57

Cat. No.: HY-19537

NI-57 is an inhibitor of bromodomain and plant homeodomain finger-containing (**BRPF**) famlily of proteins, with IC_{50}s of 3.1, 46 and 140 nM for BRPF1, BRPF2 (BRD1) and BRPF3, respectively.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NSC 228155

Cat. No.: HY-101084

NSC 228155 is an activator of **EGFR**, binds to the extracellular region of **EGFR** and enhance tyrosine phosphorylation of EGFR.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVS-BET-1

Cat. No.: HY-142265

NVS-BET-1 is a **BET bromodomain** inhibitor that regulates keratinocyte plasticity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NVS-CECR2-1

Cat. No.: HY-110374

NVS-CECR2-1, a non-BET family **Bromodomain (BRD)** inhibitor, is a potent and selective cat eye syndrome chromosome region, candidate 2 (**CECR2**) inhibitor. NVS-CECR2-1 binds to CECR2 BRD with high affinity (IC_{50}=47 nM; K_D=80 nM).



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg

OARV-771

Cat. No.: HY-145264

OARV-771 is a VHL-based **BET** degrader (PROTAC) with improved cell permeability. OARV-771 shows DC_{50}s of 6, 1, and 4 nM for Brd4, Brd2 and Brd3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ODM-207

(BET-IN-4)

Cat. No.: HY-111916

ODM-207 (BET-IN-4) is a potent **BET** bromodomain protein (**BRD4**) inhibitor, with an IC_{50} of ≤ 1 μM.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

OF-1

Cat. No.: HY-12518

OF-1 is a potent pan-BRPF **bromodomain** (BRD) inhibitor, with IC_{50} values of 270 nM, 1.2 μM for TRIM24 and BRPF1B, respectively.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

OXFBD02

Cat. No.: HY-103297

OXF BD 02 is a selective inhibitor of **BRD4(1)** (the first bromodomain of BRD4) with IC_{50} value of 382 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OXFBD04

Cat. No.: HY-135236

OXFBD04 is a potent and selective **BRD4** inhibitor with an IC_{50} of 166 nM. OXFBD04 is a potent BET bromodomain ligand with additional modest affinity for the CREBBP bromodomain. OXFBD04 has anti-cancer activity.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

P300 bromodomain-IN-1

Cat. No.: HY-146445

P300 bromodomain-IN-1 (Compoun 1u) is a potent **p300 (EP300) bromodomain** inhibitor with an IC_{50} of 49 nM. P300 bromodomain-IN-1 suppresses the expression of c-Myc and induces G1/G0 phase arrest and **apoptosis** in OPM-2 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PARP1/BRD4-IN-1

Cat. No.: HY-144338

PARP1/BRD4-IN-1 is a potent and high selective **PARP1/BRD4** inhibitor (IC_{50}s of 49 and 202 nM in PARP1 and BRD4, respectively). PARP1/BRD4-IN-1 represses the expression and activity of PARP1 and BRD4 to synergistically inhibit the malignant growth of pancreatic cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-CBP1 hydrochloride

Cat. No.: HY-19999A

PF-CBP1 hydrochloride is a highly selective inhibitor of the **CREB binding protein bromodomain (CBP BRD)**. PF-CBP1 inhibits **CREBBP** and **EP300 bromodomains** with IC_{50} of 125 nM and 363 nM respectively.



Purity: 95.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PFI-1

Cat. No.: HY-16586

PFI-1 is a selective **BET** (bromodomain-containing protein) inhibitor for BRD4 with IC_{50} of 0.22 μM in a cell-free assay.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PFI-3

Cat. No.: HY-12409

PFI-3 is a selective, potent and cell-permeable **SMARCA2/4** bromodomain inhibitor with a K_d of 89 nM.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PFI-4

Cat. No.: HY-18664

PFI-4 is a potent and selective and cell permeable BRPF1 bromodomain inhibitor (IC50 = 80 nM). Exhibits >100-fold selectivity for BRPF1 over a panel of other bromodomains including BRPF2 (BRD1), BRPF3 and BRD4.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PLK1/BRD4-IN-1

Cat. No.: HY-143471

PLK1/BRD4-IN-1 (9b) is an orally active dual **PLK1** and **BRD4** inhibitor with IC_{50} values of 22 nM and 109 nM against PLK1 and BRD4, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PLX51107

Cat. No.: HY-111422

PLX51107 is a potent and selective **BET** inhibitor, with K_ds of 1.6, 2.1, 1.7, and 5 nM for BD1 and 5.9, 6.2, 6.1, and 120 nM for BD2 of BRD2, BRD3, BRD4, and BRDT, respectively; PLX51107 also interacts with the bromodomains of CBP and EP300 (K_d, in the 100 nM range).



Purity: 99.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PNZ5

Cat. No.: HY-100696

PNZ5 is a potent and isoxazole-based **pan-BET** inhibitor with high selectivity and potency similar to the well-established (+)-JQ1, with a K_D of 5.43 nM for BRD4(1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BET Degrader-1

Cat. No.: HY-103633

PROTAC BET Degrader-1 is a PROTAC connected by ligands for **Cereblon** and **BET**, decreasing BRD2, BRD3, and BRD4 protein levels at low concentration.



Purity: 98.30%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

PROTAC BET Degrader-10

Cat. No.: HY-112718

PROTAC BET Degrader-10 is a potent BET protein **BRD4** degrader extracted from patent WO2017007612A1, example 37, connected by ligands for **Cereblon** and **BRD4**, with a DC_{50} of 49 nM.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PROTAC BET degrader-2

Cat. No.: HY-114228

PROTAC BET degrader-2 is a PROTAC connected by ligands for **Cereblon** and **BET** with an IC_{50} value of 9.6 nM in cell growth inhibition in the RS4;11 cells and capable of achieving tumor regression.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

PROTAC BET degrader-3

Cat. No.: HY-114229

PROTAC BET Degrader-3 is a PROTAC connected by ligands for **von Hippel-Lindau** and **BET**.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

PROTAC BRD2/BRD4 degrader-1

Cat. No.: HY-130612

PROTAC BRD2/BRD4 degrader-1 (compound 15) is a potent and selective BET protein **BRD4** and **BRD2** degrader, connected by ligands for **Cereblon** and **BET**. PROTAC BRD2/BRD4 degrader-1 rapidly induces reversible, long-lasting, and unexpectedly selective removal of BRD4 and BRD2 over BRD3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD4 Degrader-1

Cat. No.: HY-133131

PROTAC BRD4 Degrader-1 is a PROTAC connected by ligands for **Cereblon** and **BRD4** with an IC_{50} of 41.8 nM against BRD4 BD1. PROTAC BRD4 Degrader-1 can effectively degrade **BRD4 protein** and suppress **c-Myc** expression.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD4 Degrader-10

Cat. No.: HY-138633

PROTAC BRD4 Degrader-10 (compound 8b) is a PROTAC connected by ligands for **von Hippel-Lindau** and **BRD4**. PROTAC BRD4 Degrader-10 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC_{50} of 1.3 nM and 18 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD4 Degrader-11

Cat. No.: HY-138634

PROTAC BRD4 Degrader-11 (compound 9a) is a PROTAC connected by ligands for **von Hippel-Lindau** and **BRD4**. PROTAC BRD4 Degrader-11 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC_{50} of 0.23 nM and 0.38 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD4 Degrader-12

Cat. No.: HY-138635

PROTAC BRD4 Degrader-12 (compound 9c) is a PROTAC connected by ligands for **von Hippel-Lindau** and **BRD4**. PROTAC BRD4 Degrader-12 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC_{50} of 0.39 nM and 0.24 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD4 Degrader-13

Cat. No.: HY-138636

PROTAC BRD4 Degrader-13 (compound 9d) is a PROTAC connected by ligands for **von Hippel-Lindau** and **BRD4**. PROTAC BRD4 Degrader-13 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC_{50} of 0.025 nM and 6.0 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD4 Degrader-14

Cat. No.: HY-138637

PROTAC BRD4 Degrader-14 is a PROTAC connected by ligands for **von Hippel-Lindau** and **BRD4**, with IC_{50}s of 1.8 nM and 1.7 nM for **BRD4 BD1** and **BD2**, respectively. PROTAC BRD4 Degrader-14 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD4 Degrader-15

Cat. No.: HY-139294

PROTAC BRD4 Degrader-15 is a PROTAC connected by ligands for **von Hippel-Lindau** and **BRD4**, with IC_{50}s of 7.2 nM and 8.1 nM for **BRD4 BD1** and **BD2**, respectively. PROTAC BRD4 Degrader-15 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD4 Degrader-2

Cat. No.: HY-133136

PROTAC BRD4 Degrader-2 is a PROTAC connected by ligands for **Cereblon** and **BRD4** with an IC_{50} of 14.2 nM against **BRD4 BD1**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD4 Degrader-3

Cat. No.: HY-135558

PROTAC BRD4 Degrader-3 (compound 1004.1) is an efficacious PROTAC connected by ligands for **von Hippel-Lindau** and **BRD4**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD4 Degrader-5

Cat. No.: HY-133737

PROTAC BRD4 Degrader-5 is a PROTAC connected by ligands for **von Hippel-Lindau** and **BRD4**. PROTAC BRD4 Degrader-5 can potent degrade **BRD4** in HER2 positive and negative breast cancer cell lines.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PROTAC BRD4 Degrader-7

Cat. No.: HY-136857

PROTAC BRD4 Degrader-7 is a potent **bromodomain BRD4** degrader extracted from patent WO2020055976A1, example 1a, has IC_{50}s of 15.5 and 12.3 nM for BRD4-BD1 and BRD4-BD2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD4 Degrader-8

Cat. No.: HY-138555

PROTAC BRD4 Degrader-8 is a PROTAC connected by ligands for **von Hippel-Lindau** and **BRD4**, with IC_{50}s of 1.1 nM and 1.4 nM for **BRD4 BD1** and **BD2**, respectively. PROTAC BRD4 Degrader-8 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD4 Degrader-9

Cat. No.: HY-138632

PROTAC BRD4 Degrader-9 (compound 8a) is a PROTAC connected by ligands for **von Hippel-Lindau** and **BRD4**. PROTAC BRD4 Degrader-9 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC_{50} of 0.86 nM and 7.6 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD4 ligand-1

Cat. No.: HY-129939

PROTAC BRD4 ligand-1 is a potent **BET** inhibitor and a ligand for target BRD4 protein for PROTACT GNE-987 (HY-129937A).



Purity: 99.50%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

PROTAC BRD4-binding moiety 1

Cat. No.: HY-107442

PROTAC BRD4-binding moiety 1 is a ligand for BRD4. PROTAC BRD4-binding moiety 1 binds to cereblon ligand via a linker to form PROTAC to degrade BRD4 (HY-133136).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD9 Degrader-1

Cat. No.: HY-103632

PROTAC BRD9 Degrader-1 is a PROTAC connected by ligands for **Cereblon** and **BRD9** (IC_{50}=13.5 nM), which can be used as a selective probe useful for the study of BAF complex biology.



Purity: 98.30%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PROTAC CBP/P300 Degrader-1

Cat. No.: HY-138536

PROTAC CBP/P300 Degrader-1 is a potent **PROTAC CBP/P300** degrader. PROTAC CBP/P300 Degrader-1 potently inhibited cell viability of multiple cancer cell lines.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

QCA570

Cat. No.: HY-112609

QCA570 is a PROTAC connected by ligands for **Cereblon** and **BET**, with an IC_{50} of 10 nM for **BRD4 BD1** Protein.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

RVX-297

Cat. No.: HY-114504

RVX-297 is a potent, orally active **BET bromodomain** inhibitor with selectivity for **BD2**. RVX-297 shows IC_{50}s of 0.08, 0.05, and 0.02 μM for BRD2(BD2), BRD3(BD2), and BRD4(BD2), respectively. RVX-297 suppresses inflammatory gene expression in multiple immune cell types.



Purity: 96.59%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SDR-04

Cat. No.: HY-146741

SDR-04 is a **BET** inhibitor and exhibits strong BRD4-BD1 affinity and inhibition activity. SDR-04 potently suppresses MV4;11 cancer cell line proliferation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SF2523

Cat. No.: HY-101146

SF2523 is a highly selective and potent inhibitor of **PI3K** with IC_{50}s of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for **PI3Kα**, **PI3Kγ**, **DNA-PK**, BRD4 and mTOR, respectively.



Purity: 97.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SGC-CBP30

Cat. No.: HY-15826

SGC-CBP30 is a potent and highly selective **CBP/p300 bromodomain** (K_ds of 21 nM and 32 nM for **CBP** and **p300**, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of **BRD4 [BRD4(1)]** bound.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SGC-iMLLT

Cat. No.: HY-112804

SGC-iMLLT is a first-in-class chemical probe and a potent, selective inhibitor of **MLLT1/3-histone interactions** with an IC_{50} of 0.26 μM. SGC-iMLLT shows high binding activity towards MLLT1 YEATS domain (YD) and MLLT3 YD (AF9/YEATS3) with K_ds of 0.129 and 0.077 μM, respectively.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SGC-SMARCA-BRDVIII

Cat. No.: HY-145446

SGC-SMARCA-BRDVIII is a potent and selective inhibitor of **SMARCA2/4** and **PB1(5)**, with K_ds of 35 nM, 36 nM, and 13 nM, respectively. SGC-SMARCA-BRDVIII also inhibits **PB1(2)** and **PB1(3)**, with K_ds of 3.7 and 2.0 μM, respectively.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SIM1

Cat. No.: HY-141438

SIM1 is a potent **von Hippel-Lindau** (VHL)-based trivalent **PROTAC** capable of degradation for all **BET** family members, with preference for **BRD2** degradation (IC_{50}=1.1 nM; **Kd**=186 nM). SIM1 shows sustained anti-cancer activity.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SNDX-5613

Cat. No.: HY-136175

SNDX-5613 is a potent and specific **Menin-MLL** inhibitor with a binding K_i of 0.149 nM and a cell based IC_{50} of 10-20 nM. SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).



Purity: 98.59%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SNIPER(BRD)-1

Cat. No.: HY-111875

SNIPER(BRD)-1, consists of an **IAP** antagonist LCL-161 derivative and a **BET** inhibitor, (+)-JQ-1, connected by a linker. SNIPER(BRD)-1 induces the degradation of **BRD4** via the ubiquitin-proteasome pathway.



Purity: 98.40%
Clinical Data: No Development Reported
Size: 1 mg

SR-0813

Cat. No.: HY-145409

SR-0813 is a potent and selective **ENL/AF9 YEATS** domain inhibitor. SR-0813 has IC_{50} and EC_{50} values of 25 nM and 205 nM for ENL YEATS domain, respectively. SR-0813 has IC_{50} and EC_{50} values of 311 nM and 76 nM (CETSA) for AF9 YEATS domain, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TD-428

Cat. No.: HY-114407

TD-428 is a PROTAC connected by ligands for **Cereblon** and **BRD4**. TD-428 is a highly specific **BRD4** degrader with a DC_{50} of 0.32 nM. TD-428 is a **BET PROTAC**, which comprises TD-106 (a CRBN ligand) linked to JQ1 (a BET inhibitor). TD-428 efficiently induce BET protein degradation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-NH-CBP/p300 ligand 2

Cat. No.: HY-139707

Thalidomide-NH-CBP/p300 ligand 2 (P-007) is a **PROTAC**-based CBP and p300 degrader (extracted from patent WO2020173440).



Purity: 99.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TP-238

Cat. No.: HY-114205

TP-238 is a potent and selective dual **CECR2/BPTF** probe with IC_{50} values of 30 nM and 350 nM, respectively. TP-238 also inhibits **BRD9** with a pIC_{50} of 5.9 and is less active against other 338 kinases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TP-238 hydrochloride

Cat. No.: HY-114205A

TP-238 hydrochloride is a potent and selective dual **CECR2/BPTF** probe with IC_{50} values of 30 nM and 350 nM, respectively. TP-238 hydrochloride also inhibits **BRD9** with a pIC_{50} of 5.9 and is less active against other 338 kinases.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 10 mg

TP-472

Cat. No.: HY-100517

TP-472 is a selective **BRD7/9** inhibitor, with K_Ds of 0.34 μM and 33 nM for BRD7 and BRD9, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TPOP146

Cat. No.: HY-100697

TPOP146 is a selective **CBP/P300** benzoxazepine bromodomain inhibitor with K_d values of 134 nM and 5.02 μM for CBP and BRD4.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Trotabresib

(CC-90010)

Cat. No.: HY-137573

CC-90010 (compound 1) is a reversible and orally active **BET** inhibitor. CC-90010 is applied in the study for advanced solid tumors.



Purity: 99.57%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UMB-32

Cat. No.: HY-117997

UMB-32, a potent, selective **BRD4** inhibitor, binds BRD4 with the K_d of 550 nM, and IC_{50} of 637 nM. UMB-32 also shows potency against TAF1, a bromodomain-containing transcription factor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UMB298

Cat. No.: HY-139148

UMB298 is a potent and selective **CBP/P300** bromodomain inhibitor.



Purity: 99.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UNC 669

Cat. No.: HY-15839

UNC 669, a ligand for a methyl-lysine binding domain, is a potent **L3MBTL1** (IC_{50}=4.2 uM) and **L3MBTL3** (3.1 uM) inhibitor.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

UNC6212 (Kme2)

Cat. No.: HY-142954

UNC6212 (Kme2), a dimethyllysine (Kme2)-containing ligand, has a K_D for CBX5 of 5.7 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UNC6349 (Ket2)

Cat. No.: HY-142953

UNC6349 (Ket2), a diethyllysine (Ket2)-containing ligand, binds to wild-type CBX5, with a K_D of 3.2 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UNC6864 (Kei)

Cat. No.: HY-142952

UNC6864 (Kei), an ethylisopropyllysine (Kei)-containing ligand, binds to wild-type CBX5, with a K_D of 3.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UNC926

Cat. No.: HY-16510

UNC926 is a **methyl-lysine (Kme) reader domain** inhibitor that inhibits **L3MBTL1** with an **IC_{50}** of 3.9 μM.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UNC926 hydrochloride

Cat. No.: HY-16510A

UNC926 hydrochloride is a **methyl-lysine (Kme) reader domain** inhibitor that inhibits **L3MBTL1** with an **IC_{50}** of 3.9 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VTP50469

Cat. No.: HY-114162

VTP50469 is a potent, highly selective and orally active **Menin-MLL interaction** inhibitor with a **K_i** of 104 pM. VTP50469 has potently anti-leukemia activity.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

VTP50469 fumarate

Cat. No.: HY-114162A

VTP50469 fumarate is a potent, highly selective and orally active **Menin-MLL interaction** inhibitor with a **K_i** of 104 pM. VTP50469 fumarate has potently anti-leukemia activity.



Purity: 98.84%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

VZ185

Cat. No.: HY-114322

VZ185 is a potent, fast, and selective **von Hippel-Lindau** based dual degrader probe of **BRD9** and **BRD7** with **DC_{50}**s of 4.5 and 1.8 nM, respectively. VZ185 is cytotoxic in EOL-1 and A-402 cells, with **EC_{50}**s of 3 nM and 40 nM, respectively.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

XD14

Cat. No.: HY-110215

XD14 is a potent **BET** inhibitor with antitumor effect. It binds to BRD2, BRD3, and BRD4 with **K_d**s of 170, 380, and 160 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

XMD8-92

Cat. No.: HY-14443

XMD8-92 is a potent **ERK5 (BMK1)/BRD4** inhibitor with **K_d**s of 80 and 190 nM, respectively. XMD8-92 inhibits DCAMKL2, PLK4 and TNK1 with **K_d**s of 190, 600 and 890 nM, respectively. Anti-cancer activity.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

XP-524

Cat. No.: HY-147008

XP-524 is a potent **BET** and **EP300** inhibitor. XP-524 shows great tumoricidal activity in vivo. XP-524 prevents KRAS-induced, neoplastic transformation in vivo and extends survival in two transgenic mouse models of aggressive PDAC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

XY-06-007

Cat. No.: HY-145226

XY-06-007 is a selective and potent bump-and-hole (B&H)-**PROTAC** $BRD4_{BD1}$ L94V degrader. XY-06-007 shows a **$DC_{50,\ 6\ h}$** of 10 nM against $BRD4_{BD1}$ L94V with no degradation of off-targets. XY-06-007 demonstrates suitable pharmacokinetics for in vivo studies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Y06036

Cat. No.: HY-111502

Y06036 is a potent and selective **BET** inhibitor, which binds to the **BRD4(1)** bromodomain with **K_d** value of 82 nM. Antitumor activity.



Purity: 98.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Y06137

Cat. No.: HY-111503

Y06137 is a potent and selective **BET** inhibitor for treatment of castration-resistant prostate cancer (CRPC). Y06137 binds to the **BRD4(1)** bromodomain with a K_d of 81 nM.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Y08175

Cat. No.: HY-142743

Y08175 is a potent **CBP bromodomain** inhibitor. Y08175 exhibits considerable inhibitory effect with IC_{50}s of 37 and 178.15 nM against CBP bromodomain in AlphaScreen assay and HTRF assay, respectively. Y08175 can be used for the research of prostate cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Y08284

Cat. No.: HY-142772

Y08284 is a potent, selective, oral active **CBP bromodomain** inhibitor with an IC50 of 4.21 nM. Y08284 suppresses the proliferation of prostate cancer cell lines LNCaP, C4-2B, and 22Rv1. Antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

YM458

Cat. No.: HY-146999

YM458 is a potent **EZH2** and **BRD4** dual inhibitor with IC_{50}s of 490 nM and 34 nM, respectively. YM458 inhibits cell proliferation and colony formation and induces cell cycle arrest and **apoptosis** in solid cancer cells. YM458 can be used for researching anticancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZEN-3219

Cat. No.: HY-111977

ZEN-3219 is a **BET** inhibitor with IC_{50}s of 0.48, 0.16 and 0.47 μM for **BRD4(BD1)**, **BRD4(BD2)** and **BRD4(BD1BD2)**, respectively. ZEN-3219 can be used to form **PROTACs** to induce degradation of BRD4.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZEN-3411

Cat. No.: HY-111979

ZEN-3411 is a **BET** inhibitor with IC_{50}s of 0.05, 0.05 and 0.06 μM for **BRD4(BD1)**, **BRD4(BD2)** and **BRD4(BD1BD2)**, respectively. ZEN-3411 can be used to form **PROTACs** to induce degradation of BRD4.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZEN-3862

Cat. No.: HY-111978

ZEN-3862 is a **BET** inhibitor with IC_{50}s of 0.16 and 0.13 μM for **BRD4(BD1)** and **BRD4(BD2)** , respectively. ZEN-3862 can be used to form **PROTACs** to induce degradation of BRD4.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ziftomenib

(KO-539)

Cat. No.: HY-132001

Ziftomenib (KO-539) is a **menin-MLL interaction** inhibitor with antitumor activities (WO2017161028A1, compound 151).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

ZL0420

Cat. No.: HY-112149

ZL0420 is a potent and selective bromodomain-containing protein 4 (**BRD4**) inhibitor with IC_{50} values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

ZL0454

Cat. No.: HY-112150

ZL0454 is a potent and selective **Bromodomain-containing protein 4 (BRD4)** inhibitor with an IC_{50} of 49 and 32 nM for BD1 and BD2.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ZL0580

Cat. No.: HY-126428

ZL0580, a structurally close analog of ZL0590, induces epigenetic suppression of **HIV** via selectively binding to BD1 domain of **BRD4**.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ZL0590

Cat. No.: HY-145310

ZL0590 is a potent, orally active **BRD4 BD1**-selective inhibitor with an IC_{50} of 90 nM for human BRD4 BD1. ZL0590 exhibits significant anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZLD2218

Cat. No.: HY-144236

Considerable studies confirmed that BRD4 inhibition ameliorated kidney injury and fibrosis and ZLD2218 exhibited the most potent inhibitory activity against BRD4, with the IC_{50} value of 107 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZXH-3-26

Cat. No.: HY-122826

ZXH-3-26 is a PROTAC connected by ligands for **Cereblon** and **BRD4** with a $DC_{50/5h}$ of 5 nM. The $DC_{50/5h}$ refers to half-maximal degradation after 5 hours of treatment of ~ 5 nM.



Purity: 98.61%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

β-NF-JQ1

Cat. No.: HY-130256

β-NF-JQ1 is a **PROTAC** that recruits **Aryl Hydrocarbon Receptor** E3 ligase to target proteins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg